1. Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process;Liu;J. Pharm. Biomed. Anal.,2009
2. EMEA–CHMP, Guideline on the Limit of Genotoxic Impurities CPMP/SWP/5199/02, EMEA/CHMP/QMP/251344/2006, 28 June 2006.
3. US FDA, Guidance for industry: genotoxic and carcinogenic impurities in drug substances and products: recommended approaches (draft), December 2008, http://www.fda.gov/cder/guidance.
4. EMEA Q&A, EMEA/CHMP/SWP/431994/2007, http://www.emea.europa.eu/pdfs/human/swp/43199407en.pdf.
5. An impact analysis of the application of the threshold of toxicological concern concept to pharmaceuticals;Delaney;Regul. Toxicol. Pharmacol.,2007